Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy of Esophageal Cancer: First Clinical Experience and Dosimetric Benefits

Overview

Journal Adv Radiat Oncol

Specialty Oncology

Date 2024 Dec 4

PMID 39628955

Authors

Nicolas Bachmann

Daniel Schmidhalter

Frederic Corminboeuf

Martin D Berger

Yves Borbely

Ekin Ermis

Emanuel Stutz

Binaya K Shrestha

Daniel M Aebersold

Peter Manser

Hossein Hemmatazad

Affiliations

Soon will be listed here.

Abstract

Purpose: Radiation therapy (RT) plays a key role in the management of esophageal cancer (EC). However, toxicities caused by proximity of organs at risk (OAR) and daily target coverage caused by interfractional anatomic changes are of concern. Daily online adaptive RT (oART) addresses these concerns and has the potential to increase OAR sparing and improve target coverage. We present the first clinical experience and dosimetric investigations of cone beam CT-based oART in EC using the ETHOS platform.

Methods And Materials: Treatment fractions of the first 10 EC patients undergoing cone beam CT-based oART at our institution were retrospectively analyzed. The prescription dose was 50.4 Gy in 28 fractions. The same clinical target volume (CTV) and planning target volume (PTV) margins as for nonadaptive treatments were used. For all sessions, the timestamp of each oART workflow step, PTV size, target volume doses, mean heart dose, and lung V of both the scheduled and the adapted treatment plan were analyzed.

Results: Following automatic propagation, the CTV was adapted by the physician in 164 (59%) fractions. The adapted treatment plan was selected in 276 (99%) sessions. The median time needed for an oART session was 28 minutes (range, 14.8-43.3). Compared to the scheduled plans, a significant relative reduction of 9.5% in mean heart dose (absolute, 1.6 Gy; = .006) and 16.9% reduction in mean lung V (absolute, 2.3%; < .001) was achieved with the adapted treatment plans. Simultaneously, we observed a significant relative improvement in D99%PTV and D99%CTV by 15.3% ( < .001) and 5.0% ( = .008), respectively, along with a significant increase in D95%PTV by 5.1% ( = .003).

Conclusions: Although being resource-intensive, oART for EC is feasible in a reasonable timeframe and results in increased OAR sparing and improved target coverage, even without a reduction of margins. Further studies are planned to evaluate the potential clinical benefits.

References

Wei X, Liu H, Tucker S, Wang S, Mohan R, Cox J . Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2008; 70(3):707-14. DOI: 10.1016/j.ijrobp.2007.10.056. View

Alfred Brennsaeter J, Dahle T, Moi J, Svanberg I, Haaland G, Pilskog S . Reduction of PTV margins for elective pelvic lymph nodes in online adaptive radiotherapy of prostate cancer patients. Acta Oncol. 2023; 62(10):1208-1214. DOI: 10.1080/0284186X.2023.2252584. View

Nardone V, Giugliano F, Reginelli A, Sangiovanni A, Mormile M, Iadanza L . 4D CT analysis of organs at risk (OARs) in stereotactic radiotherapy. Radiother Oncol. 2020; 151:10-14. DOI: 10.1016/j.radonc.2020.06.048. View

Defize I, Boekhoff M, Borggreve A, van Lier A, Takahashi N, Haj Mohammad N . Tumor volume regression during neoadjuvant chemoradiotherapy for esophageal cancer: a prospective study with weekly MRI. Acta Oncol. 2020; 59(7):753-759. DOI: 10.1080/0284186X.2020.1759819. View

van der Bijl E, Remeijer P, Sonke J, van der Heide U, Janssen T . Adaptive margins for online adaptive radiotherapy. Phys Med Biol. 2022; 67(19). DOI: 10.1088/1361-6560/ac9175. View

Lin S, Wang L, Myles B, Thall P, Hofstetter W, Swisher S . Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012; 84(5):1078-85. PMC: 3923623. DOI: 10.1016/j.ijrobp.2012.02.015. View

Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M . Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(10):992-1004. DOI: 10.1016/j.annonc.2022.07.003. View

Mao W, Riess J, Kim J, Vance S, Chetty I, Movsas B . Evaluation of Auto-Contouring and Dose Distributions for Online Adaptive Radiation Therapy of Patients With Locally Advanced Lung Cancers. Pract Radiat Oncol. 2022; 12(4):e329-e338. DOI: 10.1016/j.prro.2021.12.017. View

Wu A, Bosch W, Chang D, Hong T, Jabbour S, Kleinberg L . Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. Int J Radiat Oncol Biol Phys. 2015; 92(4):911-20. PMC: 4481325. DOI: 10.1016/j.ijrobp.2015.03.030. View

10.

Boekhoff M, Defize I, Borggreve A, van Hillegersberg R, Kotte A, Lagendijk J . An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients. Radiother Oncol. 2021; 162:76-84. DOI: 10.1016/j.radonc.2021.06.038. View

11.

Konski A, Li T, Christensen M, Cheng J, Yu J, Crawford K . Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol. 2012; 104(1):72-7. PMC: 3389132. DOI: 10.1016/j.radonc.2012.04.016. View

12.

Nishikawa G, Banik P, Thawani R, Kardosh A, Wood S, Nabavizadeh N . Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades. J Gastrointest Oncol. 2022; 13(3):1454-1466. PMC: 9274047. DOI: 10.21037/jgo-22-29. View

13.

Wang J, Wei C, Tucker S, Myles B, Palmer M, Hofstetter W . Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013; 86(5):885-91. PMC: 3786201. DOI: 10.1016/j.ijrobp.2013.04.006. View

14.

Feng A, Gu H, Chen H, Shao Y, Wang H, Duan Y . Account for the Full Extent of Esophagus Motion in Radiation Therapy Planning: A Preliminary Study of the IRV of the Esophagus. Front Oncol. 2021; 11:734552. PMC: 8656362. DOI: 10.3389/fonc.2021.734552. View

15.

Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P . NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol. 2019; 141:33-40. DOI: 10.1016/j.radonc.2019.09.015. View

16.

Lee S, Bassetti M, Meijer G, Mook S . Review of MR-Guided Radiotherapy for Esophageal Cancer. Front Oncol. 2021; 11:628009. PMC: 8019940. DOI: 10.3389/fonc.2021.628009. View

17.

Shelley C, Bolt M, Hollingdale R, Chadwick S, Barnard A, Rashid M . Implementing cone-beam computed tomography-guided online adaptive radiotherapy in cervical cancer. Clin Transl Radiat Oncol. 2023; 40:100596. PMC: 9999162. DOI: 10.1016/j.ctro.2023.100596. View

18.

Liu H, Schaal D, Curry H, Clark R, Magliari A, Kupelian P . Review of cone beam computed tomography based online adaptive radiotherapy: current trend and future direction. Radiat Oncol. 2023; 18(1):144. PMC: 10475190. DOI: 10.1186/s13014-023-02340-2. View

19.

Yen A, Zhong X, Lin M, Nwachukwu C, Albuquerque K, Hrycushko B . Improved Dosimetry with Daily Online Adaptive Radiotherapy for Cervical Cancer: Waltzing the Pear. Clin Oncol (R Coll Radiol). 2024; 36(3):165-172. DOI: 10.1016/j.clon.2024.01.005. View

20.

Lin S, Hobbs B, Verma V, Tidwell R, Smith G, Lei X . Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol. 2020; 38(14):1569-1579. PMC: 7213588. DOI: 10.1200/JCO.19.02503. View